Citius Oncology shares surge 15.15% intraday after partnering with Verix AI and McKesson to boost LYMPHIR's CTCL rollout.

Citius Oncology (CTOR) surged 15.15% intraday trading after announcing a partnership with Verix AI to accelerate the commercial rollout of LYMPHIR for CTCL, alongside a distribution services agreement with McKesson for LYMPHIR. The collaboration with Verix AI highlights the company’s focus on leveraging artificial intelligence to enhance drug commercialization, while the McKesson deal strengthens LYMPHIR’s market accessibility. These developments, combined with a recent price target increase, signal growing confidence in the drug’s market potential and operational scalability, directly aligning with the stock’s sharp intraday rally.